See Recent Shionogi-Sponsored Congress Presentations
Congresses
As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.
The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.
Select a congress event or filter to view available congress presentations.
You Are Viewing Presentations
Ensitrelvir for the prevention of COVID-19 among household contacts: Key subgroup analyses of SCORPIO-PEP phase 3 study
Ensitrelvir for the prevention of COVID-19 among household contacts: Key subgroup analyses of SCORPIO-PEP phase 3 study
Ensitrelvir for the treatment of COVID-19 infection: evaluation of taste disorder and smell disorder in the phase 3 part of the phase 2/3 SCORPIO-SR randomized controlled trial
Ensitrelvir for the treatment of COVID-19 infection: evaluation of taste disorder and smell disorder in the phase 3 part of the phase 2/3 SCORPIO-SR randomized controlled trial
Ensitrelvir in hospitalized patients with SARS-CoV-2 during the Omicron epidemic: A single-center observational study
Ensitrelvir in hospitalized patients with SARS-CoV-2 during the Omicron epidemic: A single-center observational study
Ensitrelvir to prevent COVID-19 in households: SCORPIO-PEP phase III placebo-controlled trial results
Ensitrelvir to prevent COVID-19 in households: SCORPIO-PEP phase III placebo-controlled trial results
Evaluation of phenotypic cross-resistance between cefiderocol and β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US Medical Centers
Evaluation of phenotypic cross-resistance between cefiderocol and β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa isolates from US Medical Centers
Exploratory evaluation on the effect of ensitrelvir for Long COVID: a post-hoc analysis of phase 3 part of phase 2/3 in patients with mild-to-moderate COVID-19
Exploratory evaluation on the effect of ensitrelvir for Long COVID: a post-hoc analysis of phase 3 part of phase 2/3 in patients with mild-to-moderate COVID-19
You Are Viewing Congress Locations
ESCMID 2025
CROI 2025
SCCM 2025
IDWeek 2024
NACFC 2024
IAS 2024
ESCMID 2024
SCCM 2024
IDWeek 2023
CHEST 2023
ESWI 2023
ISSX 2023
PAGE 2023
